Data supplement for Davidson et al., Efficacy and Safety of MIN-101: A 12-Week Randomized, Double Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry (doi: 10.1176/appi.ajp.2017.17010122)

FIGURE S1. Flowchart of Patients' Progress Through the Study


* Including patients who dropped out after completion of Week 12 assessments due to refusal to be hospitalized at onset of open label phase: Placebo $(\mathrm{n}=10)$; MIN-101 $32 \mathrm{mg}(\mathrm{n}=9)$; MIN-101 $64 \mathrm{mg}(\mathrm{n}=4)$

FIGURE S2. Change From Baseline in the PANSS Negative Scale Scores


